Dew - you are giving real time information to stock traders now? Consorting with the enemy, eh?
This 14% discount could be meaninful - maybe SNY stays on their side of the pond and MNTA takes this market. Hope teva does not get approval ever - that would be sweet.
Interesting choice. I had also been assuming something in the 20% range.
A branded generic makes no sense at these prices - would just serve to undercut their branded product.
Only disadvantage that I see is that it might make the FDA more eager to approve Teva's offering.
MNTA is going to be making an awful lot of money in the meantime (assuming they don't go crazy on their spend). Remains to be seen what multiple the street gives them. I don't think it will be too generous as there will likely remain an overhang of doubt about the possibility of a second approval. But even at a low multiple my view is the stock still has some room to run over the next year.
Market Data 
Markets 
AI
